Vestergaard, Esben Thyssen <br/><br/>
Acipimox Acutely Increases GLP-1 Concentrations in Overweight Subjects and Hypopituitary Patients.  [electronic resource] 

 -  The Journal of clinical endocrinology and metabolism  07 2019 
 - 2581-2592 p.  digital 
<br/><br/> Publication Type: Journal Article; Pragmatic Clinical Trial; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1945-7197 
<br/><br/><label>Standard No.: </label>10.1210/jc.2018-02503  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Animals<br/>Blood Glucose--analysis<br/>Cells, Cultured<br/>Cross-Over Studies<br/>Enteroendocrine Cells--drug effects<br/>Fatty Acids, Nonesterified--metabolism<br/>Glucagon-Like Peptide 1--metabolism<br/>Glucose Tolerance Test<br/>Humans<br/>Hypolipidemic Agents--administration & dosage<br/>Hypopituitarism--blood<br/>Insulin Resistance<br/>Intestinal Mucosa--cytology<br/>Lipolysis--drug effects<br/>Male<br/>Middle Aged<br/>Overweight--blood<br/>Pilot Projects<br/>Primary Cell Culture<br/>Pyrazines--administration & dosage<br/>Rats